Synchrogenix

What Synchrogenix does

Synchrogenix is a U.S.-based specialist provider of strategic regulatory writing and related services for the pharmaceutical and biotechnology industry, founded in 1986 and headquartered in Wilmington, Delaware. The company delivers documentation across the full regulatory lifecycle — including clinical, nonclinical, and CMC writing, submission leadership for IND/NDA/BLA/MAA filings, eCTD publishing and validation, clinical disclosure and transparency, aggregate safety reporting, and document quality management. Service delivery is anchored by a writing organization of 200+ regulatory writers, editors, and submission experts with a documented track record of supporting the majority of recent FDA approvals and global submissions across FDA, EMA, and other international agencies. The company expanded via the January 2015 acquisition of ClinGenuity, and operates in close association with Veristat, a full-service clinical research organization, enabling integrated delivery across clinical operations, biostatistics, regulatory affairs, and pharmacovigilance.

Synchrogenix generates revenue through professional services engagements on a quote-based, project- and program-priced model. Go-to-market is enterprise field sales, with direct engagement with pharmaceutical sponsors and biotechnology companies at critical submission milestones (e.g., database lock, NDA/BLA/MAA preparation). Customer segmentation is vertical: pharmaceutical sponsors, biotechnology companies (including cell and gene therapy and vaccine developers), and rare disease/pediatric sponsors. Marketing is delivered through a content library of white papers, factsheets, webinars, podcasts, and case studies, with 'Talk to an expert' and RFP CTAs converting into program-level engagements. The addressable market — global medical writing — is projected to grow from $4.83B in 2024 to $10.67B in 2032 at a 10.4% CAGR, driven by oncology, rare disease, and biologics pipeline expansion, providing a strong secular backdrop.

Name

Synchrogenix

Legal name

Synchrogenix

Website

https://synchrogenix.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

101–250 employees

Short description

Synchrogenix provides strategic regulatory writing and submission services to pharmaceutical and biotechnology sponsors, covering clinical, nonclinical, and CMC documentation, eCTD publishing, and submission leadership for IND, NDA, BLA, and MAA filings globally.

Ownership category

akta.pro rank

Product category

Regulatory Writing and Submission Services

NAICS

Document Preparation Services (56141)

SIC

Miscellaneous Publishing (2741)

akta.pro primary industry

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

akta.pro secondary industries

Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN)

Keywords

• Regulatory writing services
• Medical writing services
• Pharmaceutical regulatory submissions
• Biotech regulatory documentation
• Clinical regulatory affairs

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Regulatory Writing Services: Professional services revenue generated through regulatory writing, submissions support, and consulting engagements. Services are provided to pharmaceutical, biotechnology, and life sciences sponsors requiring regulatory documentation for drug approvals.
2. Medical Writing Services: Medical writing services supporting clinical research expansion. Revenue driven by increasing clinical trial activity, regulatory complexity, and outsourcing trends in the life sciences sector.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Synchrogenix provides strategic regulatory writing and related services for the pharmaceutical and biotech industry, delivering clear and compliant documentation across clinical, nonclinical, and CMC areas. The company leads submissions for IND, NDA, BLA, and MAA filings, and supports sponsors with clinical disclosure and transparency, eCTD publishing and validation, aggregate safety reporting, and document quality management. Engagements are scope-tied, ranging from targeted expertise to full program ownership at critical submission points.

Differentiator

Problem solved

Functional benefit

Products and services

• Regulatory Writing Services Strategic regulatory writing and related services delivering clear, compliant documentation across clinical, nonclinical, and CMC areas for pharmaceutical and biotechnology sponsors preparing regulatory submissions.
• Medical Writing Services Medical writing services supporting clinical research and regulatory documentation for pharmaceutical, biotechnology, and life sciences sponsors, driven by clinical trial activity, regulatory complexity, and outsourcing trends.

Quantifiable outcome

• Rolling BLA submission delivered ahead of schedule despite shifting timelines

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators4 records

Recent moves3 records

Expansion highlights4 records

Direct peers

• Veristat: Mid-size CRO with a regulatory writing practice (IND/NDA/BLA submissions, eCTD publishing) that overlaps directly with Synchrogenix's offerings. Provided source data attributes Synchrogenix's described talent pool and capabilities to Veristat, indicating close operational overlap or a brand/affiliation relationship.
• Worldwide Clinical Trials: Mid-size global CRO with a focused regulatory writing and submissions offering that closely mirrors Synchrogenix's positioning — mid-sized alternative frequently considered by biotech sponsors.
• Premier Research: Specialty CRO with a strong regulatory writing practice particularly in rare disease, oncology, and pediatric programs — competes directly with Synchrogenix in the same therapeutic niches.
• Celerion: Early-phase clinical research organization offering regulatory writing and submission support to small and mid-sized biopharma sponsors — comparable scale and customer profile to Synchrogenix.
• Trilogy Writing & Consulting: Boutique regulatory and medical writing consultancy specializing in clinical study reports, IBs, and submission documents — the closest pure-play specialist comp for Synchrogenix's service offering.

Broad incumbents

• Parexel International: Global full-service CRO offering regulatory writing, medical writing, eCTD publishing, and submission services as part of a broader clinical and biometrics portfolio — directly competes for the same enterprise pharma writing budgets.
• IQVIA: Largest CRO with integrated medical/regulatory writing, regulatory operations, and submission capabilities bundled into enterprise clinical development contracts — a key competitor for sponsor writing budgets.
• ICON plc: Full-service global CRO offering regulatory and medical writing, eCTD submissions, and clinical documentation as part of its clinical research services portfolio — direct overlap for sponsor-level writing engagements.
• Syneos Health: Global clinical and commercial solutions provider with a medical/regulatory writing practice that competes with specialized writing firms, particularly for biotech sponsor programs.
• Medpace: Mid-to-large full-service CRO with in-house regulatory and medical writing capabilities supporting biopharma sponsors from IND through submission — competes for the same regulatory writing scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/synchrogenix
• YouTubeyoutube.com/@veristat
• Facebookfacebook.com/synchrogenix
• LinkedInlinkedin.com/company/synchrogenix

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synchrogenix